Какова цена за Neumora Therapeutics, Inc. Common Stock (NMRA)

Цена за Neumora Therapeutics, Inc. Common Stock (NMRA) Это $1.35

Какова рыночная капитализация для Neumora Therapeutics, Inc. Common Stock (NMRA)

Рыночная капитализация для Neumora Therapeutics, Inc. Common Stock (NMRA) Это $249.21M

Прибыль Neumora Therapeutics, Inc. Common Stock (NMRA)

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.

Год	Прибыль	Изменить
Недостаточно данных для указанных дат.

Год

Прибыль

Изменить

Недостаточно данных для указанных дат.

Компания	Прибыль	Разница в прибыли	Страна
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Moderna, Inc. MRNA.US	$-3.09B	-	US
CSL Limited CSL.AX	$-4.02B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Компания

Прибыль

Разница в прибыли

Страна